Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation  

肝癌肝移植术后受体预后相关因素的研究进展（英文）

作　　者：Li-ying WANG Shu-sen ZHENG 

机构地区：[1]Department of Ultrasound, Shaoxing Second Hospital [2]Key Laboratory of Combined Multi-organ Transplantation, Ministry of Health, Division of Hepatobiliary and Pancreatic Surgery,Department of Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2018年第7期497-504,共8页浙江大学学报（英文版）B辑（生物医学与生物技术）

基　　金：Project supported by the National Natural Science Foundation of China(No.81121002);the National S&T Major Project of China(No.2012ZX10002017)

摘　　要：Hepatocellular carcinoma（HCC） is one of the most prevalent malignant tumors worldwide. Liver transplantation（LT） is known as a curative and therapeutic modality. However, the survival rates of recipients after LT are still not good enough because of tumor recurrence. To improve the survival rates of recipients after LT, identifying predictive factors for prognosis after LT and establishing a model assessing prognosis are very important to HCC patients. There has recently been a lot of clinical and basic research on recurrence and prognosis after LT. Progress has been made, especially in selection criteria for LT recipients and risk factors for predicting prognosis after LT. Hangzhou criteria, in line with China＇s high current incidence rate of primary liver, are first proposed by Chinese scholars of LT, and are accepted world-wide, and make an important contribution to the development of LT.研究肝癌肝移植患者术后生存与影响生存的各影响因素之间的关系,并评价各影响因素及移植标准的价值。筛选有效的预测肝癌预后的影响因素,可帮助建立肝移植术后肿瘤预后预警机制,对改善肝癌肝移植受体的术后预后具有重要意义。杭州标准是被国际移植学界广泛接受的肝癌肝移植标准,在引领肝癌肝移植领域的发展中做出了重要贡献。

关 键 词：Hepatocellular carcinoma Liver transplantation RECURRENCE Risk factor PROGNOSIS 

分 类 号：R36[医药卫生—病理学]